Syntheses, Structural Snapshots, Solution Redox Properties, and Cytotoxic Performances of Designated Ferrocene Scaffolds Appended with Organostannyl(IV) benzoates en Route for Human Hepatic Carcinoma

Abstract

Although several strategies have been established to circumvent the limitations of platinum-based chemotherapy, the basic problems still persist. For this purpose, the new series of heterobimetallic formulations [FcLnSnPh3] (1, 3, and 9)], [FcLnSnBu3]n (2, 4 and 8), [FcL3SnCy3] (10), and [FcL3SnR3(MeOH)] (R = Me (5), Et (6), or Pr (7)), where FcLn (n = 1–3) refers to the isomeric 2-/3-/4-ferrocenylbenzoates, was synthesized which can target cancer cells and successively support functional iron deficiencies during chemotherapy. Compounds 1–10 have been characterized by elemental analysis, and their spectroscopic properties were investigated using IR, NMR, electronic, and fluorescence techniques. The molecular structures of metallo proligands FcL1H and FcL3H and the six heterobimetallic compounds 2, 3, 5–7, and 10 have been determined by X-ray crystallography. The redox properties of FcLnH and their compounds 1–10 were also investigated by cyclic voltammetry. In vitro cytotoxic activities of compounds 1–4, ...